Omicron sub-variants BA.4, BA.5 make up more than 50% of U.S. COVID cases - CDC
Reuters
Published Jun 28, 2022 10:38AM ET
(Reuters) - The fast-spreading BA.4 and BA.5 sub-variants of Omicron are estimated to make up a combined 52% of the coronavirus cases in the United States as of June 25, the U.S. Centers for Disease Control and Prevention (CDC) said on Tuesday.
The two sublineages accounted for more than a third of U.S. cases for the week of June 18. They were added to the World Health Organization's monitoring list in March and designated as variants of concern by the European Centre for Disease Prevention and Control.
Several vaccine makers including Pfizer Inc (NYSE:PFE), Moderna (NASDAQ:MRNA) Inc and Novavax (NASDAQ:NVAX) Inc are testing versions of their COVID vaccines updated to combat the Omicron variant.
Pfizer and Moderna have said their new vaccines also appear to work against the subvariants, even though that protection is not as strong as against BA.1.
Outside experts to the U.S. Food & Drug Administration are meeting on Tuesday to discuss whether to change the design of COVID-19 vaccines in order to combat future variants.
BA.4 made up 15.7% of the variants in the United States for the week of June 25, while BA.5 made up 36.6% of the variants, according to CDC estimates.
The seven-day moving average of U.S. COVID-19 cases stood at 101,378 as of June 25, up 2.9% from a week earlier.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.